Skip to main content
News Icon

News categories: Publication

Cerebral dysfunctions caused by sepsis during aging

A differentiated look at the relationship between sepsis and acute cerebral dysfunction

Sepsis occurs when the body's own immune reactions against an infection inflicts damage to its own organs and tissues. Such systemic inflammation is a life-threatening condition and one of the most severe complications of infectious diseases. It may be caused by bacteria, viruses, fungi or parasites.

Systemic inflammations caused by Sepsis may induce an acute cerebral dysfunction known as sepsis- associated encephalopathy (SAE). Recent data from intensive care units show, that half of all patients with sepsis also develop SAE. Patients surviving a sepsis show an increased prevalence of sustained cognitive impairments for several years after initial sepsis onset.

Prof. Michael Heneka is Director of the Department of Neurodegenerative Disorders and a member of the Cluster of Excellence ImmunoSensation2 at the University Clinics Bonn. Heneka's and his team's efforts in basic and translational research focus on the field of neurodegeneration and neuroinflammation: Besides Alzeimers disease, amyotrophic lateral sclerosis, and multiple sclerosis, Prof. Henekas research is focssed on septic encephalopathy. Together with young researcher Tatsuya Manabe, Prof. Heneka now published a nuanced review on the relationship between sepsis and acute cerebral dysfunction.

Until today, it is largely unclear why SEA is developed only by some but not all sepsis patients. This also holds true for the factors determining the persistence of SAE. Based on the chronology of pathology and the dynamic changes in cognition upon sepsis onset, Heneka and Manabe dissect the cerebral effects of sepsis. The scientists discuss sepsis associated neuroinflammation, alternations in neuronal synapses as well as neurovascular changes. They also outline potential factors contributing to the development and persistence of SAE in older patients. In focus are both medical issues like sedatives and their side effects, as well as conditions like renal dysfunction or latent virus reactivation.

As severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) was reported to cause viral sepsis in more than half of the hospitalized patients suffering from severe Covid-19, the researchers close their consideration with a linking to COVID-19: Recent data shows that COVID-19 infections can lead to the loss of neuron and neuronal integrity and hence impair brain functioning. The underlying mechanisms remain to be elucidated, but may include encephalitis, vasculopathy or vasculitis, effects of systemic inflammation, induction of autoimmune reactions and peripheral organ dysfunctions. Hence, Heneka and Manabe postulate that some of the mechanisms that underpin neuropathology in SAE may also be relevant to delirium and persisting cognitive impairments that are seen in patients with severe COVID-19.

Tatsuya Manabe has joined the Heneka lab as a PhD student in 2017. He has been fascinated with the significant roles of the innate immunity in neurodegenerative diseases such as Alzheimer’s disease. His current interest focuses on the microglia-synapse interactions and innate immune memory in particular after the systemic inflammation, on the basis of which he has been working for the sepsis-associated encephalopathy project.


Publication

Tatsuya Manabe and Michael T. Heneka: Cerebral dysfunctions caused by sepsis during aging. Nature Reviews Immunology. https://www.nature.com/articles/s41577-021-00643-7

Related news

Tracking glioblastoma cell spread in human brain tissue

News categories: Publication

Core2Edge: How tumor cells conquer the brain

Glioblastoma is an aggressive brain tumor that infiltrates deep into the surrounding brain tissue. Even after surgery, tumor cells remain in the brain and the tumor recurs. Bonn researchers have now developed Core2Edge, a model based entirely on human tissue that captures these hard-to-access infiltration zones at the tumor margin. The model enables investigation of the invasive front and direct assessment of new drug candidates in human tissue - without the need for animal testing. The study of the Brain Tumor Translational Research Group has now been published in Nature Protocols.
View entry
Mikrochip zur Wiederherstellung zentralen Sehvermögens bei fortgeschrittener Makuladegeneration.

News categories: Publication

Approval of a Novel Retinal Implant Technology

A novel retinal implant is offering people with geographic atrophy the opportunity to regain part of their central vision for the first time. Geographic atrophy is a severe late stage of age-related macular degeneration. An international research team led by Prof. Frank G. Holz of the UKB and the University of Bonn demonstrated in an international clinical trial that the majority of participants experienced significant improvements in visual acuity. The novel retinal implant technology has now received approval for routine clinical use in Europe, making it available beyond clinical trials.
View entry
Authors

News categories: Publication

The Gut as a Key Player in Immunotherapy for MS

B-cell depletion therapies, in which B cells of the immune system, which may drive disease activity in multiple sclerosis (MS), are temporarily removed, have contributed significantly to improved treatment for patients in recent years. Researchers from Bonn, along with their collaborators, have uncovered a previously unknown mechanism through which B-cell depletion therapies contribute to a better disease course in patients with MS. Surprisingly, the treatment appears to exert part of its beneficial effect by mobilizing regulatory immune cells that naturally reside in the gut.
View entry

Back to the news overview